Daniel Mrak

rheumatologist in training

[Bonelli Lab @MichaelBonell10]

New insights into T cell - fibroblast interactions and development of synovial pathotypes in #RA patients.
Thanks to all coauthors!

https://t.co/4JNqkekfWL

[Bonelli Lab @MichaelBonell10]

Advanced immunophenotyping: A powerful tool for immune profiling, drug screening, and a personalized treatment appr… https://t.co/zbmS0T40WP

[Atherosclerosis @ATHjournal]

In this large-scale cohort (1222 👥) of symptomatic #PAD, no association of ⬆️Lp(a) with 🫀mortality was found over a median observation period of 5 y

Read the study by @daniel_mrak &al👇
https://t.co/cP8WokvrCa

#Lpa #Atherosclerosis #CardioTwitter @EASCongress @society_eas

[Daniel Mrak @daniel_mrak]

Advantage of mRNA #COVID booster vaccination as compared to vector in non-seroconverted #immunosuppressed patients: new guidance available! Big thanks to all contributors.

https://t.co/jx8e1VTIri

[Daniel Mrak @daniel_mrak]

Rituximab and 4th COVID-19 vaccination:
Continuation of rituximab impaires "boostability".
Thanks to our fantastic coautors!
#COVID19 #Booster #rituximab
https://t.co/mwfRRe0qo8

[Bonelli Lab @MichaelBonell10]

Finally out: our randomized controlled trial provides evidence for efficacy of Tocilizumab in PMR
https://t.co/pxIj5MWVxl

[Annals of the Rheumatic Diseases @eular_ARD]

Check out the latest findings on #COVID19 vaccination & rituximab:

▶️vaccinacion induce antibodies in RTX-treated patients once peripheral B cells at least partially repopulate
▶️specific T cells were detected, independent of humoral immune response

https://t.co/lxjbdTWgaV

[Bonelli Lab @MichaelBonell10]

Finally out: new evidence for efficacy and safety of a #COVID19 booster vaccination in #Rituximab-treated patients. Thanks to all the authors! @MedUni_Wien @kim3_med @DanielAletaha @leoheinz @AberleJudith
https://t.co/X2efQvSYpY